Amended Claims

Claim 1 (canceled).

2. **(currently amended)** A pharmaceutical composition**, wherein:**

the composition comprises ~~**comprising**~~ one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a weight average particle size of about 500 nm to about 900 nm**;** ~~**, and wherein**~~

the selective cyclooxygenase-2 inhibitory drug is a compound of formula**:**



; [[where]]

R^3 is **[[a]]** methyl or amino**;** ~~**group,**~~

R^4 is hydrogen**,** **[[or a]]** C_{1-4} alkyl**,** or C_{1-4} alkoxy**;** ~~**group,**~~

X is N or CR^5**; [[where]]**

R^5 is hydrogen or halogen**;** **[[,]]** and

Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl**,** or halomethyl ~~**groups**~~.

Claim 3 (canceled).

4. **(currently amended)** The composition of Claim **2** **[[1]]** wherein the dose units are in the form of discrete solid articles.

5. **(original)** The composition of Claim 4 wherein the solid particles are tablets or capsules.

6. **(currently amended)** The composition of Claim **2** **[[1]]** that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.

7. **(original)** The composition of Claim 6 wherein the substantially homogeneous flowable mass is a liquid suspension.

Claims 8-11 (canceled).

12. **(currently amended)** The composition of Claim **2** **[[1]]** wherein **Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a ~~the five to six-membered~~** ring **[[is]]** selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole, and pyridine rings substituted at no more than one position.

13. **(currently amended)** The composition of Claim **2** **[[1]]** wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-l-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.

14. **(original)** The composition of Claim 13 wherein the selective cyclooxygenase-2 inhibitory drug is celecoxib.

15. **(original)** The composition of Claim 14 comprising about 10 mg to about 1000 mg celecoxib in each dose unit.

Claims 16-18 (cancelled).

19. **(currently amended)** A method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, **wherein:**

the method comprises ~~**comprising**~~ orally administering one or more dose units of a composition one to about six times a day; ~~**, wherein**~~

the composition comprises a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a weight average particle size of about 500 nm to about 900 nm; ~~**, and wherein**~~

the selective cyclooxygenase-2 inhibitory drug is a compound of formula:



; **[[where]]**

R^3 is **[[a]]** methyl or amino; ~~**group,**~~

R^4 is hydrogen, **[[or a]]** C_{1-4} alkyl, or C_{1-4} alkoxy; ~~**group,**~~

X is N or CR^5; **[[where]]**

R^5 is hydrogen or halogen; **[[,]]** and

Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl, or halomethyl ~~**groups**~~.

20. **(previously presented)** The method of Claim 19 wherein the medical condition or disorder is accompanied by acute pain.

21. **(previously presented)** The method of Claim 19 wherein the dose units are in the form of discrete solid articles.

22. **(previously presented)** The method of Claim 21 wherein the solid articles are tablets or capsules.

23. **(previously presented)** The method of Claim 19 that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.

24. **(currently amended)** The method of Claim 19 wherein **Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a** ~~**the five to six-membered**~~ ring **[[is]]** selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole, and pyridine rings substituted at no more than one position.

25. **(previously presented)** The method of Claim 19 wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.

26. **(currently amended)** A method of making a medicament useful in treatment or prophylaxis of a COX-2 mediated condition or disorder, **wherein:**

the method **comprises** ~~**comprising**~~ incorporation of a selective cyclooxygenase-2 inhibitory drug of low water solubility into a pharmaceutical composition comprising one or more orally deliverable dose units, wherein the drug is in the form of solid particles having a weight average particle size of about 500 nm to about 900 nm**;** ~~**, and wherein**~~

the selective cyclooxygenase-2 inhibitory drug is a compound of formula**:**



; [[where]]

R^3 is **[[a]]** methyl or amino**;** ~~**group,**~~

R^4 is hydrogen, **[[or a]]** C_{1-4} alkyl, or $\underline{C_{1-4}}$ alkoxy; ~~group,~~

X is N or CR^5; **[[where]]**

R^5 is hydrogen or halogen; **[[,]]** and

Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl, or halomethyl ~~groups~~.

27. **(previously presented)** The method of Claim 26 wherein the dose units are in the form of discrete solid articles.

28. **(previously presented)** The method of Claim 27 wherein the solid articles are tablets or capsules

29. **(previously presented)** The method of Claim 25 that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.

30. **(currently amended)** The method of Claim 25 wherein **Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a** ~~**the five to six-membered**~~ ring **[[is]]** selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole, and pyridine rings substituted at no more than one position..

31. **(previously presented)** The method of Claim 25 wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.